Fractional diffusion on the human proteome as an alternative to the multi-organ damage of SARS-CoV-2

被引:11
|
作者
Estrada, Ernesto [1 ,2 ]
机构
[1] Univ Zaragoza, Inst Univ Matemat & Aplicac, Zaragoza 50009, Spain
[2] Govt Aragon, ARAID Fdn, Zaragoza 50018, Spain
关键词
FUNCTIONAL RECEPTOR; ANOMALOUS DIFFUSION; RANDOM-WALKS; NETWORKS; CORONAVIRUS; CONSENSUS; PROTEINS; MEDICINE; COVID-19; ACE2;
D O I
10.1063/5.0015626
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
The coronavirus 2019 (COVID-19) respiratory disease is caused by the novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which uses the enzyme ACE2 to enter human cells. This disease is characterized by important damage at a multi-organ level, partially due to the abundant expression of ACE2 in practically all human tissues. However, not every organ in which ACE2 is abundant is affected by SARS-CoV-2, which suggests the existence of other multi-organ routes for transmitting the perturbations produced by the virus. We consider here diffusive processes through the protein-protein interaction (PPI) network of proteins targeted by SARS-CoV-2 as an alternative route. We found a subdiffusive regime that allows the propagation of virus perturbations through the PPI network at a significant rate. By following the main subdiffusive routes across the PPI network, we identify proteins mainly expressed in the heart, cerebral cortex, thymus, testis, lymph node, kidney, among others of the organs reported to be affected by COVID-19.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] SARS-Cov-2 Interactome with Human Ghost Proteome: A Neglected World Encompassing a Wealth of Biological Data
    Cardon, Tristan
    Fournier, Isabelle
    Salzet, Michel
    [J]. MICROORGANISMS, 2020, 8 (12) : 1 - 12
  • [42] Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
    Jacome, Rodrigo
    Alberto Campillo-Balderas, Jose
    Ponce de Leon, Samuel
    Becerra, Arturo
    Lazcano, Antonio
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [43] Classical and alternative receptors for SARS-CoV-2 therapeutic strategy
    Masre, Siti Fathiah
    Jufri, Nurul Farhana
    Ibrahim, Farah Wahida
    Raub, Sayyidi Hamzi Abdul
    [J]. REVIEWS IN MEDICAL VIROLOGY, 2021, 31 (05) : 1 - 9
  • [44] Therapeutic antibodies and alternative formats against SARS-CoV-2
    Winiger, Rahel R.
    Perez, Laurent
    [J]. ANTIVIRAL RESEARCH, 2024, 223
  • [45] Could tear be an alternative specimen for SARS-CoV-2 detection?
    Cetinkaya, Yasemin Fatma
    Hosbul, Tugrul
    Artuk, Cumhur
    Karacayli, Ceren
    Bakir, Fatih
    [J]. TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2022, 47 (05): : 680 - 685
  • [46] Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
    Rodrigo Jácome
    José Alberto Campillo-Balderas
    Samuel Ponce de León
    Arturo Becerra
    Antonio Lazcano
    [J]. Scientific Reports, 10
  • [47] ACE2-Independent Alternative Receptors for SARS-CoV-2
    Lim, Suhyeon
    Zhang, Monica
    Chang, Theresa L.
    [J]. VIRUSES-BASEL, 2022, 14 (11):
  • [48] Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
    Pruijssers, Andrea J.
    George, Amelia S.
    Schafer, Alexandra
    Leist, Sarah R.
    Gralinksi, Lisa E.
    Dinnon, Kenneth H., III
    Yount, Boyd L.
    Agostini, Maria L.
    Stevens, Laura J.
    Chappell, James D.
    Lu, Xiaotao
    Hughes, Tia M.
    Gully, Kendra
    Martinez, David R.
    Brown, Ariane J.
    Graham, Rachel L.
    Perry, Jason K.
    Du Pont, Venice
    Pitts, Jared
    Ma, Bin
    Babusis, Darius
    Murakami, Eisuke
    Feng, Joy Y.
    Bilello, John P.
    Porter, Danielle P.
    Cihlar, Tomas
    Baric, Ralph S.
    Denison, Mark R.
    Sheahan, Timothy P.
    [J]. CELL REPORTS, 2020, 32 (03):
  • [49] SARS-CoV-2 Variants Divergently Infect And Damage Cardiomyocytes
    Mok, Bobo
    Kwok, Maxwell
    Li, Hung Sing
    Ling, Lowell
    Lai, Angel
    Chan, Paul
    Yan, Bryan
    Chen, Hong Lin
    Poon, Ellen
    [J]. CIRCULATION RESEARCH, 2023, 133
  • [50] Myocardial Damage by SARS-CoV-2: Emerging Mechanisms and Therapies
    Ho, Huyen Tran
    Peischard, Stefan
    Strutz-Seebohm, Nathalie
    Klingel, Karin
    Seebohm, Guiscard
    [J]. VIRUSES-BASEL, 2021, 13 (09):